Recruiting

Observational StudyNon-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.

Sponsor:

Clindove Research LLC

Code:

NCT07106879

Conditions

Cardiovascular Diseases

Metabolic Syndrome

Obesity

Prediabetes

Mental Health Disorders

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

Blood Work

Study Details

Brief summary:

DOVE-MET-COME-100 is a single site prescreening survey study designed to identify adults who may be eligible for future industry-sponsored clinical trials. A physician will oversee the informed consent process, after which participants will be surveyed on demographics, medical history, current health conditions and symptoms. The study team may also collect basic health information, including vital signs, urine drug tests, blood samples and pregnancy tests (if applicable). A physician will review each participant's medical history in a one-on-one interview to assess potential fit for upcoming trials. If needed, the doctor may contact the participant's current doctors or pharmacies to gather more information for eligibility review.

Conditions

Cardiovascular Diseases

Metabolic Syndrome

Obesity

Prediabetes

Mental Health Disorders

Study ID

NCT07106879

Start date

Jul 30, 2025

Status verified date

Aug, 2025

Completion date

Dec 1, 2030

Anticipated

Primary completion date

Jul 1, 2030

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

Any participant of age 18 years and over
Who are willing to provide informed consent and participate in the pre-screening study and comply with study procedures.

Exclusion Criteria:

Pregnant or breastfeeding individuals
Individuals having severe cognitive impairment or inability to provide informed consent
Individuals having acute psychiatric emergencies requiring immediate intervention/hospitalization
Individuals who are currently participating in another research study that conflicts with pre-screening data collection
Individuals having known history of drug/alcohol misuse
Individuals having medical conditions that, in the investigator's opinion, could compromise the integrity of the screening process or pose significant risks to the participant's health.

Study Design

Enrollment

7000 participants

Anticipated

Interventions and Outcome Measures

Arms

All Participants

Participants undergoing metabolic and/or psychiatric assessments through blood work and structured clinical evaluations, as outlined in the study protocol.

Interventions

Blood Work

Collection of blood samples for metabolic and other necessary biomarker analysis, including Hemoglobin A1c (HbA1c), Lipid Panel, Liver and Kidney function tests and other protocol-defined assays.

Primary outcome measure

Number of participants who express interest in industry-sponsored clinical research [ Time Frame: 5 years ]

Central Contacts and Locations

Central contacts

Nelly Cohen, MD

516-518-3239 study@clindoveresearch.com

Locations

Clindove Research LLC

Recruiting

Brooklyn, New York, United States, 11221

Contacts

Nelly Cohen, MD

516-518-3239 study@clindoveresearch.com

Principal Investigator:

Nelly Cohen, MD

More Information

Sponsor

Clindove Research LLC

Last update posted

Aug 12, 2025

Last verified

Aug, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-07. This information was provided to ClinicalTrials.gov by Clindove Research LLC on 2025-08-12.